TABLE 1.
Characteristics of the study population
| Patient | Antiretroviral therapya | Age (mo) | Baseline plasma RNA (log copies/ml) | Baseline % CD4 | Time (wk) to RNA <400 | Length of follow-up (mo) |
|---|---|---|---|---|---|---|
| P-1048 | ZDV/3TC/NVP | 0.5 | 4.5 | 34 | 12 | 29 |
| P-1216 | ZDV/3TC/NVP | 2.8 | 5.7 | 14 | 12 | 27 |
| P-1228 | ZDV/3TC/NVP | 1.1 | 5.3 | 47 | 16 | 32 |
| P-1232 | ZDV/3TC/NVP/ABV | 3.0 | 5.0 | 40 | 16 | 21 |
| P-1235 | ZDV/3TC/NVP/ABV | 2.2 | 5.3 | 24 | 2 | 27 |
| P-1238 | ZDV/3TC/NVP/ABV | 3.0 | 3.3 | 52 | 0.5 | 24 |
| P-1246 | ZDV/3TC/NVP/ABV | 0.8 | 5.2 | 54 | 8 | 24 |
| P-1247 | ZDV/3TC/NVP/ABV | 1.1 | 4.3 | 63 | 4 | 21 |
| P-1222 | d4T/3TC/NVP/NLF | 1.8 | 5.5 | 36 | 16 | 18 |
| P-1223 | d4T/3TC/NVP/NLF | 1.5 | 5.2 | 34 | 8 | 18 |
| P-1231 | d4T/3TC/NVP/NLF | 1.7 | 5.8 | 52 | 16 | 16 |
| P-1233 | d4T/3TC/NVP/NLF | 1.9 | 5.6 | 30 | 12 | 16 |
| P-1251 | d4T/3TC/NVP/NLF | 2.2 | 5.2 | 19 | 8 | 18 |
| P-1252 | d4T/3TC/NVP/NLF | 1.6 | 5.4 | 46 | 8 | 18 |
| P-1260 | d4T/3TC/NVP/NLF | 2.4 | 5.2 | 55 | 12 | 18 |
| P-3743 | ZDV/ddI/NVP | 2.5 | 5.5 | 44 | 8 | 56 |
| P-3742 | ZDV/ddI/NVP | 2.5 | 5.5 | 57 | 20 | 56 |
a
ABV, abacavir.